Table 2

Change in efficacy and patient-reported outcomes 4, 8 and 12 weeks after rescue in rescued patients from RA-BEAM

Baricitinib to baricitinib (n=35)Adalimumab to baricitinib (n=40)
Score at time of rescueChange from rescue visitScore at time of rescueChange from rescue Visit
Week 4 (n=34)Week 8 (n=33)Week 12 (n=30)Week 4 (n=40)Week 8 (n=39)Week 12 (n=33)
DAS28-ESR6.1 (1.3)−0.93 (0.18)***−1.51 (0.20)***−1.73 (0.22)***6.2 (1.3)−1.38 (0.17)***−1.69 (0.19)***−1.92 (0.21)***
CDAI39.3 (15.2)−14.1 (2.1)***−20.5 (2.2)***−22.3 (2.3)***36.4 (14.5)−14.8 (2.0)***−17.8 (2.0)***−20.2 (2.2)***
SDAI40.8 (16.0)−14.1 (2.3)***−21.0 (2.3)***−23.1 (2.5)***38.9 (14.5)−16.2 (2.1)***−19.2 (2.2)***−21.8 (2.3)***
Patient’s assessment of pain53.8 (21.0)−13.1 (3.8)***−13.8 (3.9)***−18.3 (4.0)***56.4 (25.4)−14.5 (3.5) ***−21.5 (3.6)***−24.1 (3.7)***
HAQ-DI1.42 (0.72)−0.19 (0.08)*−0.28 (0.08)***−0.34 (0.09)***1.46 (0.66)−0.37 (0.07) ***−0.47 (0.08)***−0.49 (0.09)***
CRP, mg/L14.9 (23.5)−0.45 (4.35)−4.79 (4.49)−8.50 (5.04)25.3 (29.8)−13.50 (4.00)***−14.10 (4.13)***−16.00 (4.69)***
ESR, mm/h36.5 (27.7)0.71 (3.40)−4.49 (4.16)−5.05 (4.76)51.9 (35.4)−16.60 (3.16)***−21.80 (3.85)***−19.06 (4.48)***
  • Score at the time of rescue data are mean (SD); change from baseline data is LSM (SE).

  • *p≤0.05; **p≤0.01; ***p≤0.001 from within-group mean change from the last visit prior to rescue using MMRM.

  • CDAI, Clinical Disease Activity Index;CRP, C reactive protein; DAS28-ESR, disease activity score using 28-joint count with erythrocyte sedimentation rate;ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index;LSM, least squares mean;MMRM, mixed-effects model repeated measures;SDAI, Simplified Disease Activity Index.